Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KN026 and KN046 in HER2-positive solid tumors
NCT04040699Phase 1Completed
- Sponsor
- Peking University
- Start
- Sep 2019
- Primary completion
- Sep 2022
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of anbenitamab and erfonrilimab in HER2-positive solid tumor (HER2+), sponsored by Peking University. Primary endpoints: Dose-Limiting Toxicity at 28 days, Objective Response Rate at 2 years and 1 more. Started Sep 2019; status: completed.
02
Drugs
anbenitamaberfonrilimab
03
Conditions
HER2-positive solid tumor (HER2+)
Beyond the preview
Go deeper on NCT04040699.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04040699.